499 related articles for article (PubMed ID: 32936732)
1. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
4. On the road to ending the COVID-19 pandemic: Are we there yet?
Case JB; Winkler ES; Errico JM; Diamond MS
Virology; 2021 May; 557():70-85. PubMed ID: 33676349
[TBL] [Abstract][Full Text] [Related]
5. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
7. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
8. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
Front Immunol; 2021; 12():771242. PubMed ID: 34880867
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccinations: The unknowns, challenges, and hopes.
Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
Soni B; Kabra R; Singh S
J Interferon Cytokine Res; 2021 Jul; 41(7):244-257. PubMed ID: 34280026
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
Front Immunol; 2021; 12():809244. PubMed ID: 35046961
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus vaccine development: from SARS and MERS to COVID-19.
Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
16. Will Omicron end the pandemic? Here's what experts say.
Adam D
Nature; 2022 Feb; 602(7895):20-21. PubMed ID: 35102287
[No Abstract] [Full Text] [Related]
17. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches.
Marei HE; Althani A; Afifi N; Pozzoli G; Caceci T; Angelini F; Cenciarelli C
Mol Biol Rep; 2021 Sep; 48(9):6513-6524. PubMed ID: 34398427
[TBL] [Abstract][Full Text] [Related]
18. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
[TBL] [Abstract][Full Text] [Related]
19. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
Behr MA; Divangahi M; Schurr E
J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
[TBL] [Abstract][Full Text] [Related]
20. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
Murano K; Guo Y; Siomi H
Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
